First Hawaiian Bank Purchases 154,694 Shares of Haleon plc (NYSE:HLN)

First Hawaiian Bank raised its position in shares of Haleon plc (NYSE:HLN) by 103.3% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 304,434 shares of the company’s stock after purchasing an additional 154,694 shares during the period. First Hawaiian Bank’s holdings in Haleon were worth $2,585,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of HLN. FMR LLC raised its position in Haleon by 22.2% during the 3rd quarter. FMR LLC now owns 53,951,936 shares of the company’s stock valued at $449,420,000 after purchasing an additional 9,812,040 shares in the last quarter. Wellington Management Group LLP raised its position in shares of Haleon by 164.6% in the 4th quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company’s stock worth $111,454,000 after acquiring an additional 8,423,475 shares in the last quarter. Envestnet Asset Management Inc. raised its position in shares of Haleon by 121.2% in the 3rd quarter. Envestnet Asset Management Inc. now owns 5,931,187 shares of the company’s stock worth $49,407,000 after acquiring an additional 3,249,517 shares in the last quarter. Cambiar Investors LLC bought a new position in shares of Haleon in the 4th quarter worth $15,225,000. Finally, Kayne Anderson Rudnick Investment Management LLC raised its position in shares of Haleon by 6,593.0% in the 3rd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,692,937 shares of the company’s stock worth $14,102,000 after acquiring an additional 1,667,643 shares in the last quarter. 6.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently commented on HLN. HSBC began coverage on Haleon in a research report on Wednesday, April 17th. They issued a “buy” rating for the company. Argus reissued a “buy” rating on shares of Haleon in a research report on Tuesday, March 26th. Finally, Berenberg Bank initiated coverage on Haleon in a research report on Wednesday, June 5th. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy”.

Haleon Stock Up 1.1 %

Shares of HLN stock opened at $8.46 on Thursday. Haleon plc has a 1-year low of $7.70 and a 1-year high of $8.96. The stock’s fifty day moving average price is $8.36 and its 200 day moving average price is $8.33. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.04 and a quick ratio of 0.73. The company has a market cap of $38.63 billion, a price-to-earnings ratio of 28.20, a price-to-earnings-growth ratio of 2.25 and a beta of 0.26.

Haleon (NYSE:HLN) last announced its earnings results on Wednesday, May 1st. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.01. Haleon had a return on equity of 13.17% and a net margin of 9.68%. The firm had revenue of $3.70 billion for the quarter, compared to the consensus estimate of $3.71 billion. On average, research analysts expect that Haleon plc will post 0.46 earnings per share for the current fiscal year.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.